Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris

Last updated: June 13, 2023
Sponsor: Badr University
Overall Status: Active - Recruiting

Phase

3

Condition

Rash

Psoriasis And Psoriatic Disorders

Scalp Disorders

Treatment

Vitamin E

Acetyl cysteine

Clinical Study ID

NCT05906498
Acetylcysteine in Psoriasis
  • Ages 18-65
  • All Genders

Study Summary

This study aims to assess the effect of adding N-acetyl cysteine (NAC) alone or in combination with Vitamin E to conventional therapy in improving the clinical outcome, oxidative stress, and inflammation in patients with mild psoriasis vulgaris

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult Patients from 18 to 65 years.
  2. Gender: both males and females.
  3. Mild psoriatic patients in the active phase (score < =3)
  4. Patients diagnosed with mild psoriasis in the active phase (score less than or equal
  1. using PASI score.

Exclusion

Exclusion Criteria:

  1. Inactive psoriasis vulgaris patients.
  2. Alcohol consumption
  3. Any other autoimmune diseases.
  4. Pregnant or lactating women.
  5. Patients with serious illness and any systemic failure (cardiovascular, renal, orrespiratory)
  6. Patients with major psychiatric or mental illness.
  7. Intake of any antioxidants in the previous 3 months
  8. Patients of chronic diseases, like hypertension, heart problems
  9. Patients with history of bleeding, ulcers, or uncontrollable heartburn.
  10. Patients taking anticancer medications that can aggravate psoriasis vulgaris such asmercaptopurine, vinblastine, actinomycin, and Radiation

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Vitamin E
Phase: 3
Study Start date:
December 01, 2022
Estimated Completion Date:
December 31, 2023

Study Description

The study will include 60 Mild psoriatic patients in the active phase (score <, =3) using PASI score. The PASI is a widely used instrument that assesses and grades the severity of psoriatic lesions and the patient's response to treatment. They will assigned randomly into 3 groups. Each group will contain 20 patients. the first group will receive Standard treatment for mild psoriatic patients (topical steroid and salicylic acid), the second group will receive Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral, 30 minutes before breakfast, for 8 weeks. the third group will receive Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet,30 minutes before breakfast Plus, vitamin E (1000 mg) daily, oral soft gelatin capsule for 8 weeks.

PASI=Psoriasis Area and Severity Index

Connect with a study center

  • Al-Haud Al-Marsoud Hospital

    Cairo,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.